Table 1

Fibroblast growth factor receptor inhibitors undergoing clinical trials for treatment of urothelial carcinoma

NCT numberPhaseInterventionsURL
1NCT04197986Phase IIIInfigratinib https://ClinicalTrials.gov/show/NCT04197986
2NCT02278978Phase IIBIBF1120 https://ClinicalTrials.gov/show/NCT02278978
3NCT03390504Phase IIIErdafitinib https://ClinicalTrials.gov/show/NCT03390504
4NCT03410693Phase II | Phase IIIRogaratinib (BAY1163877) https://ClinicalTrials.gov/show/NCT03410693
5NCT02608125Phase IPRN1371 https://ClinicalTrials.gov/show/NCT02608125
6NCT02872714Phase IIPemigatinib https://ClinicalTrials.gov/show/NCT02872714
7NCT03473756Phase I | Phase IIRogaratinib (BAY1163877) https://ClinicalTrials.gov/show/NCT03473756
8NCT04045613Phase I | Phase IIDerazantinib https://ClinicalTrials.gov/show/NCT04045613
9NCT04003610Phase IIPemigatinib https://ClinicalTrials.gov/show/NCT04003610
10NCT00790426Phase IIDovitinib (TKI258) https://ClinicalTrials.gov/show/NCT00790426
11NCT04228042Phase IInfigratinib https://ClinicalTrials.gov/show/NCT04228042
12NCT04492293Phase IIICP-192 https://ClinicalTrials.gov/show/NCT04492293
13NCT02365597Phase IIErdafitinib https://ClinicalTrials.gov/show/NCT02365597
14NCT03123055Phase I | Phase IIVofatamab (B-701) https://ClinicalTrials.gov/show/NCT03123055
15NCT02052778Phase I | Phase IITAS-120 https://ClinicalTrials.gov/show/NCT02052778
16NCT04294277Phase IIPemigatinib https://ClinicalTrials.gov/show/NCT04294277
17NCT02401542Phase I | Phase IIVofatamab https://ClinicalTrials.gov/show/NCT02401542
18NCT03914794Phase IIPemigatinib https://ClinicalTrials.gov/show/NCT03914794
19NCT02393248Phase I | Phase IIPemigatinib https://ClinicalTrials.gov/show/NCT02393248